{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:23:32Z","timestamp":1783441412512,"version":"3.54.6"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>As the use of long-acting glucagon-like peptide-1 (GLP-1) drugs in the community grows rapidly, an increasing number of patients in the ICU will be affected by the preexisting GLP-1 therapy. This review highlights recent major advances in the use of GLP-1 drugs and their impact on gastrointestinal function, aiming to assist intensive care clinicians in developing informed management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Although the gastrointestinal inhibitory effects of GLP-1 therapy are well established, this is not clearly associated with inpatient complications. The risk of pulmonary aspiration peri-operatively is low and GLP-1 therapy does not clearly increase this risk peri-operatively. Similarly, there is no clear association with either small intestinal obstruction or acute pancreatitis. The potential impact on enteral nutrition provision is unlikely to be detrimental in the acute phase of critical illness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A systematic approach is necessary to assess gastrointestinal function and monitor for complications. Gastric ultrasound and prokinetic therapy may be useful peri-operatively to detect retained gastric contents and mitigate the risk of pulmonary aspiration. Future research may elaborate the role of GLP-1 therapy in the acute setting for stress hyperglycaemia in the critically ill.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001376","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T23:00:06Z","timestamp":1774738806000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness"],"prefix":"10.1097","volume":"32","author":[{"given":"Aniket","family":"Nadkarni","sequence":"first","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Adelaide"},{"name":"Department of Intensive Care, Royal Adelaide Hospital, Adelaide"},{"name":"Department of Intensive Care, Austin Hospital, Austin Health, Heidelberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Deane","sequence":"additional","affiliation":[{"name":"Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne."},{"name":"Department of Intensive Care, Royal Melbourne Hospital, Melbourne Health, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Plummer","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Adelaide"},{"name":"Department of Intensive Care, Royal Adelaide Hospital, Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"R1-20260430","first-page":"8","article-title":"Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"issue":"(Suppl 1)","key":"R2-20260430","article-title":"850-P: trends in GLP-1RA use among individuals with type 2 diabetes (T2D) and\/or obesity\u2014insights from a nationwide electronic health record system, 2010\u20132023","volume":"73","author":"Li","year":"2024","journal-title":"Diabetes"},{"issue":"(Suppl 1)","key":"R3-20260430","article-title":"1409-P: changing trends in glucose-lowering drug initiation for type 2 diabetes in the era of tirzepatide","volume":"73","author":"Patorno","year":"2024","journal-title":"Diabetes"},{"issue":"(Suppl 2)","key":"R4-20260430","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R5-20260430","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI118411","article-title":"Gastric emptying and release of incretin hormones after glucose ingestion in humans","volume":"97","author":"Schirra","year":"1996","journal-title":"J Clin Invest"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1476-5381.2011.01561.x","article-title":"Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion","volume":"165","author":"Parker","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R7-20260430","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/cc9039","article-title":"Bench-to-bedside review: the gut as an endocrine organ in the critically ill","volume":"14","author":"Deane","year":"2010","journal-title":"Crit Care"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"R9-20260430","first-page":"84","article-title":"Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men","volume":"109","author":"Schirra","year":"1997","journal-title":"Proc Assoc Am Physicians"},{"key":"R10-20260430","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"R11-20260430","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsboll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20260430","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"R13-20260430","doi-asserted-by":"crossref","first-page":"bqae155","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"key":"R14-20260430","doi-asserted-by":"crossref","first-page":"279530","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp Diabetes Res"},{"key":"R15-20260430","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"key":"R16-20260430","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/jc.2003-030049","article-title":"Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes","volume":"88","author":"Meier","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20260430","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ajcn\/68.3.525","article-title":"Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men","volume":"68","author":"Naslund","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"R18-20260430","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/CCM.0b013e3181d9d87a","article-title":"Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia","volume":"38","author":"Deane","year":"2010","journal-title":"Crit Care Med"},{"key":"R19-20260430","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2337\/db15-0893","article-title":"The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial","volume":"65","author":"Thazhath","year":"2016","journal-title":"Diabetes"},{"key":"R20-20260430","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","article-title":"Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy","volume":"43","author":"Nakatani","year":"2017","journal-title":"Diabetes Metab"},{"key":"R21-20260430","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","article-title":"Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects","volume":"179","author":"Keller","year":"2012","journal-title":"Regul Pept"},{"key":"R22-20260430","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R23-20260430","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2337\/dc14-1984","article-title":"Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial","volume":"38","author":"Meier","year":"2015","journal-title":"Diabetes Care"},{"issue":"(Suppl 1)","key":"R24-20260430","article-title":"MON-681 dulaglutide commonly known as trulicity; an anti-diabetic medication causing small bowel obstruction","volume":"4","author":"Gandhi","year":"2020","journal-title":"J Endocr Soc"},{"key":"R25-20260430","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.therap.2020.02.024","article-title":"Incretin-based drugs and intestinal obstruction: a pharmacovigilance study","volume":"75","author":"Gudin","year":"2020","journal-title":"Therapie"},{"key":"R26-20260430","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/dom.13420","article-title":"Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity","volume":"20","author":"Nexoe-Larsen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R27-20260430","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/jcph.940","article-title":"Effect of albiglutide on cholecystokinin-induced gallbladder emptying in healthy individuals: a randomized crossover study","volume":"57","author":"Shaddinger","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R28-20260430","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R29-20260430","doi-asserted-by":"crossref","first-page":"A2334","DOI":"10.1016\/j.chest.2023.07.1569","article-title":"A rare case of a large bowel obstruction due to tirzepatide","volume":"164","author":"Gordon","year":"2023","journal-title":"Chest"},{"key":"R30-20260430","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"R31-20260430","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J"},{"issue":"(Suppl_1)","key":"R32-20260430","first-page":"S6","article-title":"Summary of revisions: standards of care in diabetes\u20142025","volume":"48","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"R33-20260430","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"R34-20260430","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R35-20260430","first-page":"100","article-title":"Efficacy and safety of once-weekly semaglutide 1.0\u200amg vs. once-daily liraglutide 1","volume":"46","author":"Capehorn","year":"2020","journal-title":"2\u200amg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) Diabetes Metab"},{"key":"R36-20260430","doi-asserted-by":"crossref","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R37-20260430","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R38-20260430","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R39-20260430","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMc2410532","article-title":"Semaglutide for chronic kidney disease in type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"Reply N Engl J Med"},{"key":"R40-20260430","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R41-20260430","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ando.2022.12.423","article-title":"Dual GIP\/GLP-1 receptor agonists: New advances for treating type-2 diabetes","volume":"84","author":"Scheen","year":"2023","journal-title":"Ann Endocrinol"},{"key":"R42-20260430","doi-asserted-by":"crossref","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R43-20260430","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/oby.23525","article-title":"Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you","volume":"30","author":"Jalleh","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"R44-20260430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u200amg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"R45-20260430","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"R46-20260430","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R47-20260430","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2 4\u200amg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"R48-20260430","first-page":"e71569","article-title":"Population-level interest in glucagon-like peptide-1 receptor agonists for weight loss using google trends statistics in a 12-month retrospective analysis: an infodemiology and infoveillance study","volume":"16","author":"Shareef","year":"2024","journal-title":"Cureus"},{"key":"R49-20260430","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R50-20260430","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R51-20260430","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.dld.2021.04.029","article-title":"Nonalcoholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","volume":"54","year":"2022","journal-title":"Dig Liver Dis"},{"key":"R52-20260430","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"R53-20260430","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jama.2020.19400","article-title":"Gastrointestinal complications in critically ill patients with and without COVID-19","volume":"324","author":"El Moheb","year":"2020","journal-title":"JAMA"},{"key":"R54-20260430","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/aas.14222","article-title":"Use of prokinetic agents in hospitalised adult patients: a scoping review","volume":"67","author":"Crone","year":"2023","journal-title":"Acta Anaesthesiol Scand"},{"key":"R55-20260430","first-page":"463","article-title":"Gastrointestinal function in critically ill patients","volume":"26","author":"Reintam Blaser","year":"2023","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R56-20260430","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13054-024-05192-8","article-title":"Core outcome set of daily monitoring of gastrointestinal function in adult critically ill patients: a modified Delphi consensus process (COSMOGI)","volume":"28","author":"Bachmann","year":"2024","journal-title":"Crit Care"},{"key":"R57-20260430","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrendo.2014.202","article-title":"Gastric emptying and glycaemia in health and diabetes mellitus","volume":"11","author":"Phillips","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"R58-20260430","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/anae.16117","article-title":"Preoperative gastric ultrasound in patients at risk of pulmonary aspiration: a prospective observational cohort study","volume":"78","author":"Baettig","year":"2023","journal-title":"Anaesthesia"},{"key":"R59-20260430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R60-20260430","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1811687","article-title":"Energy-dense versus routine enteral nutrition in the critically ill","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"R61-20260430","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00134-017-4880-3","article-title":"Early goal-directed nutrition versus standard of care in adult intensive care patients: the single-centre, randomised, outcome assessor-blinded EAT-ICU trial","volume":"43","author":"Allingstrup","year":"2017","journal-title":"Intensive Care Med"},{"key":"R62-20260430","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jama.2025.9110","article-title":"Augmented enteral protein during critical illness: the TARGET Protein Randomized Clinical Trial","volume":"334","author":"Summers","year":"2025","journal-title":"JAMA"},{"key":"R63-20260430","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","article-title":"Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"key":"R64-20260430","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/jdi.14005","article-title":"Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy","volume":"14","author":"Kobori","year":"2023","journal-title":"J Diabetes Investig"},{"key":"R65-20260430","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.gie.2024.04.2900","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients","volume":"100","author":"Nadeem","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"R66-20260430","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2024.03.015","article-title":"Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use","volume":"167","author":"Yeo","year":"2024","journal-title":"Gastroenterology"},{"key":"R67-20260430","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cgh.2024.04.038","article-title":"Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes","volume":"23","author":"Barlowe","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R68-20260430","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cgh.2017.11.024","article-title":"Incidence of gastric-to-pulmonary aspiration in patients undergoing elective upper gastrointestinal endoscopy","volume":"16","author":"Bohman","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R69-20260430","doi-asserted-by":"crossref","first-page":"e080340","DOI":"10.1136\/bmj-2024-080340","article-title":"Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study","volume":"387","author":"Alkabbani","year":"2024","journal-title":"BMJ"},{"key":"R71-20260430","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/ALN.0000000000004776","article-title":"ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists","volume":"140","author":"Ushakumari","year":"2024","journal-title":"Anesthesiology"},{"key":"R72-20260430","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bja.2024.01.001","article-title":"Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration","volume":"132","author":"van Zuylen","year":"2024","journal-title":"Br J Anaesth"},{"key":"R73-20260430","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0310057X251355288","article-title":"2025\u200aADS\/ANZCA\/GESA\/NACOS clinical practice recommendations on the peri-procedural use of GLP-1\/GIP receptor agonists","volume":"53","author":"Hocking","year":"2025","journal-title":"Anaesth Intensive Care"},{"key":"R74-20260430","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes","volume":"111","author":"Faillie","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R75-20260430","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","article-title":"Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: scandinavian cohort study","volume":"22","author":"Ueda","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R76-20260430","doi-asserted-by":"crossref","DOI":"10.1007\/s00592-025-02525-z","article-title":"Association of GLP-1 receptor agonists with risk of intestinal obstruction in patients with type 2 diabetes mellitus: a retrospective cohort study","author":"Gao","year":"2025","journal-title":"Acta Diabetol"},{"key":"R77-20260430","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R78-20260430","first-page":"206","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol (Torino)"},{"key":"R79-20260430","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R80-20260430","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1345\/aph.1Q417","article-title":"Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients","volume":"46","author":"Pinelli","year":"2012","journal-title":"Ann Pharmacother"},{"key":"R81-20260430","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/CCM.0000000000000035","article-title":"The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study","volume":"42","author":"Galiatsatos","year":"2014","journal-title":"Crit Care Med"},{"key":"R82-20260430","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","author":"Sokos","year":"2007","journal-title":"Am J Cardiol"},{"key":"R83-20260430","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.jvca.2013.06.021","article-title":"Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kohl","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R84-20260430","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.amjcard.2008.06.029","article-title":"Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes","volume":"102","author":"Mussig","year":"2008","journal-title":"Am J Cardiol"},{"key":"R85-20260430","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"L\u00f8nborg","year":"2012","journal-title":"Eur Heart J"},{"key":"R86-20260430","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/db13-1849","article-title":"Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study","volume":"63","author":"L\u00f8nborg","year":"2014","journal-title":"Diabetes"},{"key":"R87-20260430","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1161\/CIRCULATIONAHA.116.024088","article-title":"Neuroprotective effects of the glucagon-like peptide-1 analog exenatide after out-of-hospital cardiac arrest: a randomized controlled trial","volume":"134","author":"Wiberg","year":"2016","journal-title":"Circulation"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:00:46Z","timestamp":1777586446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001376","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}